Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023943 | 0.84 | PTGS2 (0.43) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4020138 | 0.84 | HDAC3 (0.46) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4185306 | 0.82 | PTGS2 (0.40) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4020107 | 0.82 | MAPT (0.48) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4021465 | 0.82 | PTGS2 (0.47) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4344518 | 0.81 | HDAC3 (0.47) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4196773 | 0.81 | PTGS1 (0.48) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4025699 | 0.81 | HDAC3 (0.47) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4026611 | 0.81 | HDAC3 (0.42) | PTGS2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4019134 | 0.80 | HDAC3 (0.54) | PTGS2HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504519-B2 | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-03-17 | — | — | US | claimed |
| JP-2008506680-A | — | — | 2008-03-06 | — | — | JP | claimed |
| US-20080021084-A1 | Derivatives Of Pyrazoline, Procedure For obtaining Them And Use Thereof As Therapeutic Agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-24 | — | — | US | claimed |
| EP-1773782-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-04-18 | — | — | EP | claimed |
| WO-2006011005-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | claimed |
| US-7504519-B2 | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| US-20080021084-A1 | Derivatives Of Pyrazoline, Procedure For obtaining Them And Use Thereof As Therapeutic Agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-24 | — | — | US | disclosed |
| EP-1773782-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011005-A1 | DERIVATIVES OF PYRAZOLINE, PROCEDURE FOR OBTAINING THEM AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021084-A1 | Derivatives Of Pyrazoline, Procedure For obtaining Them And Use Thereof As Therapeutic Agents | CYP3A5, HRH2, PTGS1 | PTGS2 44/4885HDAC3 751/4885HDAC1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.